Table 2.
Therapeutic agents targeting macrophages and myeloid-derived suppressive cells recruitment in interventional clinical trials currently recruiting or not yet recruiting. Data acquired from the U.S. National library of medicine (http://clinicaltrials.gov, accessed on 16 January 2019).
| Therapeutic Agent | Therapeutic Agent Description | Cancer Type | Clinical Trial Reference (Phase) |
|---|---|---|---|
| Pexidartinib (PLX3397) | CSF-1R 1 inhibitor | Advanced solid tumors Giant cell tumor Melanoma Pancreatic/Colorectal cancer Gastrointestinal stromal cancer Advanced solid tumors Gastric cancer |
NCT02734433 (-) NCT02371369 (3) NCT02975700 (1/2) NCT02777710 (1) NCT03158103 (1) NCT01525602 (1) NCT03694977 (2) |
| ARRY-382 | CSF-1R inhibitor | Advanced solid tumors | NCT02880371 (2) |
| BLZ945 | CSF-1R inhibitor | Advanced solid tumors | NCT02829723 (1/2) |
| JNJ-40346527 | CSF-1R inhibitor | Prostate cancer | NCT03177460 (1) |
| Emactuzumab | CSF-1R antibody | Squamous cell carcinoma | NCT03708224 (2) |
| DCC-3014 | CSF-1R inhibitor | Advanced malignant neoplasm | NCT03069469 (1) |
| Chiauranib | Tyrosine kinase inhibitor | Ovarian cancer Small Cell Lung cancer Hepatocellular carcinoma |
NCT03166891 (1) NCT03216343 (1) NCT03245190 (1) |
| IMC-CS4 (LY3022855) |
CSF-1R blocking agent | Pancreatic cancer Melanoma |
NCT03153410 (1) NCT03101254 (1/2) |
| Cabiralizumab (FPA008) |
CSF-1R antibody | Pancreatic cancer Melanoma/Non-small cell lung cancer/Renal cell carcinoma Resectable biliary tract cancer |
NCT03697564 (2) NCT03502330 (1) NCT03768531 (2) |
| SNDX-6352 (UCB6352) | CSF-1R antibody | Advanced malignant neoplasm | NCT03238027 (1) |
| PD 0360324 | CSF-1 antibody | Ovarian cancer | NCT02948101 (2) |
| Nilotinib | Tyrosine kinase inhibitor | Malignant solid neoplasms Soft tissue sarcoma |
NCT02029001 (2) NCT03784014 (3) |
| Lacnotuzumab (MCS110) | CSF-1 antibody | Melanoma | NCT03455764 (1/2) |
1 CSF-1R, Colony-stimulating factor-1 receptor.